trending Market Intelligence /marketintelligence/en/news-insights/trending/JCihUlaJzrWS-zKqx1peGQ2 content esgSubNav
In This List

DelMar's lead drug candidate secures US FDA's fast track status

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


DelMar's lead drug candidate secures US FDA's fast track status

DelMar Pharmaceuticals Inc. secured the U.S. Food and Drug Administration's fast track designation for VAL-083, its lead product candidate to treat a rare type of brain cancer.

VAL-083, also known as dianhydrogalactitol, is a DNA-targeting agent being developed as a treatment for recurrent glioblastoma.

The status applies to two ongoing clinical trials evaluating the treatment.

Separate from those trials, VAL-083 is also being investigated in patients newly diagnosed with a type of brain cancer known as MGMT-unmethylated glioblastoma and patients with recurrent platinum-resistant ovarian cancer.